BFEC
HAE icon

Benjamin F. Edwards & Company’s Haemonetics HAE Stock Holding History

Benjamin F. Edwards & Company’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$5K Sell
60
-44
-42% -$3.87K ﹤0.01% 1870
2024
Q1 		$9K Buy
104
+15
+17% +$1.18K ﹤0.01% 1726
2023
Q4 		$8K Buy
+89
New +$7.69K ﹤0.01% 1720
2014
Q1 		– Sell
-43
Closed -$2K – 923
2013
Q4 		$2K Buy
+43
New +$1.77K ﹤0.01% 867

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Benjamin F. Edwards & Company's HAE Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its Haemonetics (HAE) stake by 42% in Q2 2024, selling an estimated $3.87K and leaving 60 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1870.

Benjamin F. Edwards & Company first reported a position in HAE in Q4 2013 and has held it in 4 quarters since. The position peaked at $9K in Q1 2024. 317 funds tracked by Wall St. Rank hold HAE as of Q2 2024.

  • Benjamin F. Edwards & Company held 60 shares of Haemonetics worth $5K as of Q2 2024.
  • Benjamin F. Edwards & Company sold 44 Haemonetics shares in Q2 2024, an estimated $3.87K.
  • Haemonetics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1870 holding.
  • Benjamin F. Edwards & Company first reported a position in Haemonetics in Q4 2013 and has held it in 4 quarters since.
  • Benjamin F. Edwards & Company's Haemonetics position peaked at $9K in Q1 2024.
  • 317 funds tracked by Wall St. Rank held Haemonetics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.